Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Greenwich LifeSciences (Nasdaq: GLSI) announced that its Board of Directors has extended the lock-up on shares held by directors, officers and existing pre-IPO investors until January 31, 2027, approximately 76 months after its IPO.
Rhea-AI Summary
Greenwich LifeSciences (Nasdaq: GLSI) announced that its Board of Directors has extended the lock-up on shares held by directors, officers and existing pre-IPO investors until January 31, 2027, approximately 76 months after its IPO. During this period, these holders generally cannot sell common stock unless the Board modifies the lock-up.
After that date, sales of these shares are expected to be limited by a leak-out plan, also subject to Board changes. The Board may at any time end all or part of the 100% lock-up, or implement a pre-determined leak-out and/or 10b5-1 selling program, and such decisions may or may not be disclosed. According to Greenwich LifeSciences, its Phase III FLAMINGO-01 trial of GLSI-100 has more than doubled enrollment and event rate, screened over 1,500 patients, and is attracting interest from leading clinicians and hospitals in up to 200 sites in the US and Europe.
Positive
- Insider and pre-IPO lock-up extended to January 31, 2027 (~76 months post-IPO)
- Board flexibility to modify lock-up, leak-out restrictions and 10b5-1 programs at any time
- Phase III FLAMINGO-01 trial enrollment and event rate reported as more than doubled
- Over 1,500 patients screened and interest from up to 200 US/EU sites reported
Negative
- None.
Details
Market move: GLSI +7.94% in the Aug 10 session. IPO lock-up extension
On Aug 10, the day this news came out, GLSI closed 7.94% above the previous close. Argus tracked a peak move of +8.2% during that session. Our momentum scanner recorded 19 alerts for this stock that day.
Data tracked by StockTitan Argus for the Aug 10 session.
Key Figures
- Lock-up extension date
- January 31, 2027
- Directors, officers, and existing pre-IPO investors
- IPO lock-up duration
- approximately 76 months
- From the date of the Company's IPO
- Shares under lock-up
- 100%
- Lock-up that the Board could modify
- Potential trial sites
- up to 200 sites
- United States and Europe
- Patients screened
- over 1,500 patients
- FLAMINGO-01 clinical trial
- Enrollment and event rate
- more than doubling
- FLAMINGO-01 enrollment and event rate
- GP2 peptide length
- 9 amino acid
- Transmembrane peptide of the HER2 protein
Historical Context
-
UK approval expanded FLAMINGO-01 and added collaboration with The Royal Marsden.
-
Trial redesign expanded enrollment and preliminary analysis indicated reduced recurrence rates.
-
EMA approved combining HLA populations in randomized FLAMINGO-01 arms.
-
EMA approved commercially manufactured GP2 for use in the clinical trial.
-
Open-label immune response data were presented from the non-HLA-A*02 arm.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
phase iii clinical trial medical
fast track regulatory
10b5-1 selling program financial
transmembrane peptide medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to January 31, 2027 which is approximately 76 months from the date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors. After January 31, 2027, the quantity of these locked-up shares that can be sold daily and over various periods of time will be restricted under a leak-out plan unless otherwise modified by the Board of Directors.
The Board could choose to end all or a small percentage of the
CEO Snehal Patel commented, "We attended and presented at the BIO conference in June 2026 and plan to attend the BIO-Europe conference later this year, where strategic and financing transactions can be originated or concluded. With the further derisking of the Phase III clinical trial, more than doubling of enrollment and event rate, interest from leading clinicians and hospitals in up to 200 sites in the US and Europe, screening of over 1,500 patients, and the transformation of the interim analysis into a big pharma like study similar in design to recent large breast cancer studies, we are expecting a continued up-tick in the quantity and seriousness of such discussions."
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.